AdvaMed President and CEO Stephen J. Ubl issued the following statement in response to a document issued by the Blue Cross and Blue Shield Association (BC/BS) suggesting that implementation of the International Classification of Diseases (ICD-10) coding system might increase improper and fraudulent Medicare billings: "AdvaMed strongly disputes the information contained in the Blue Cross/Blue Shield Association document. We believe it lacks specificity and contains no solid data to support its conclusions. AdvaMed (http://www.advamed.org/publicdocs/PR-333.htm)
Simplifying Global Compliance
Recommended Products
GMP Inspection Preparation Checklist: A Tool for Internal Auditing
This management report includes more than 650 items organized in three sections covering all aspects of quality manufacturing.
Biological Risk Evaluation and Management for Medical Devices
Report shows how the FDA incorporates the two ISO standards in its medical device development policy, how the EU version of the two standards differs in significant ways and how the EU Medical Device Regulation may require further changes in the European standards.
Editor's Picks
Health Canada Opens Consultation on ‘Pause the Clock’ Proposal
The agency would be able to pause the clock for medical device applications linked together that have different review times.
FDA Approves First Immuno-Oncology Drug for Certain Patients Previously Treated for Lung Cancer
The agency said continuing approval for Opdivo may depend on the drug showing clinical benefit in future clinical trials.